Proposed pharmacokinetic-pharmacodynamic breakpoint of garenoxacin and other quinolones.

Proposed pharmacokinetic-pharmacodynamic breakpoint of garenoxacin and other quinolones. Jpn J Infect Dis. 2017 Sep 11;: Authors: Yamagishi Y, Shibata T, Nakagawa S, Nomura N, Mitsuyama J, Mikamo H Abstract The pharmacokinetic-pharmacodynamic (PK-PD) breakpoints (BPs) of garenoxacin (GRNX) and other oral quinolones were calculated using the Monte Carlo simulation (MCS) based on the distribution of changes in their plasma concentrations. PK-PD BPs of 400 mg once a day (QD) of GRNX for the free area under the curve/minimum inhibitory concentration (fAUC/MIC) for 30 of Streptococcus pneumoniae and 100 of Gram-negative bacteria: (G (-)) were 0.5 and 0.125 μg/mL, respectively. PK-PD BPs of other quinolones for S. pneumoniae/G(-) were 1/0.25 μg/mL for levofloxacin (LVFX) 500 mg QD, 0.5/0.125 μg/mL for moxifloxacin (MFLX) 400 mg QD, 0.0625/0.0156 μg/mL for sitafloxacin (STFX) 50 mg twice a day (BID) (100 mg QD), and 0.125/0.0313 μg/mL for STFX 100 mg BID. We also investigated hypothetical probability of target attainments (PTAs) of fAUC/MIC for community-acquired pneumonia (CAP) using MCS, in consideration of isolation frequencies of three main causative pathogens of CAP; S. pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. As for PTA against hypothetical CAP in adults, PTA of fAUC/MIC was 100% with GRNX and MFLX, 96-97% with STFX at 100 mg BID, 45-46% with LVFX, and 53-58% with STFX at 100 mg QD and 50 mg BID. Based on the PK-PD BP,...
Source: Japanese Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Jpn J Infect Dis Source Type: research

Related Links:

Abstract Delafloxacin is a novel fluoroquinolone with activity against Gram-positive, Gram-negative and atypical pathogens, including fluoroquinolone non-susceptible MRSA. The microbiological results of a phase 3 clinical trial in community acquired pneumonia comparing delafloxacin [300 mg IV with option to switch to 450 mg orally every 12h to moxifloxacin 400 mg IV with option to switch to 400 mg orally QD] were determined. Patients from 4 continents, predominately Europe but also South America, and Asia, were enrolled. The microbiological intent-to-treat (MITT) population included 520 patients and 60.5% of these...
Source: Antimicrobial Agents and Chemotherapy - Category: Microbiology Authors: Tags: Antimicrob Agents Chemother Source Type: research
Conclusion: AECOPD have a major impact on the quality of life. They are a major cause of hospital admission and health care utilization. Pseudomonas species was the commonest. If done well, it can replace the costlier diagnostic methods like Immunodiffusion. Also antibiogram can help in effective treatment.
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Tags: Respiratory infections Source Type: research
AbstractLefamulin (BC-3781) is the first systemic pleuromutilin antibiotic found to be safe and effective in the treatment of community-acquired bacterial pneumonia (CABP) in humans. This novel antibiotic was developed to combat the increasing incidence of bacterial resistance to current therapies. As the first semisynthetic pleuromutilin for systemic use in humans, lefamulin has demonstrated efficacy against the most common bacteria responsible for CABP, including strains exhibiting resistance to macrolides, fluoroquinolones, tetracyclines, vancomycin, and beta-lactams. In vitro studies have demonstrated efficacy againstS...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
This study was designed to investigate pneumonia-related hospitalisation rates and trends from 2009 to 2016 prior to the introduction of nationally funded PCV vaccination. METHODS: Using national public statistic data available from the National Institute of Public Health - National Institute of Hygiene, annual hospitalisation rates for pneumonia were analysed, categorised by aetiology and age (
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Haemophilus influenzae (Hi) can cause invasive diseases such as meningitis, pneumonia, or sepsis. Typeable Hi includes six serotypes (a through f), each expressing a unique capsular polysaccharide. The capsule, e...
Source: BMC Genomics - Category: Genetics & Stem Cells Authors: Tags: Research article Source Type: research
AbstractObjectivesThere is increasing evidence indicating an association between invasive non-typeable Haemophilus influenzae (NTHi) infection in pregnancy and early pregnancy loss. As the diagnosis relies on microbiological investigation of post-mortem placental and foetal samples, a significant proportion of NTHi-related pregnancy loss remains unrecognised. To better characterise NTHi in septic abortion, we report NTHi cases associated with early pregnancy loss.MethodsWe reviewed all post-mortems at
Source: Infection - Category: Infectious Diseases Source Type: research
Conclusions: The PHiD-CV vaccination program in Brazil has resulted in important reductions of pneumococcal disease and substantial cost savings. Instead of switching PCVs, expanding vaccine coverage or investing in other health care interventions would be a more efficient use of resources to improve the health of the population in Brazil.
Source: The Pediatric Infectious Disease Journal - Category: Infectious Diseases Tags: Vaccine Reports Source Type: research
Abstract Haemophilus influenzae type b (Hib) causes various invasive infections, such as meningitis, septic arthritis, and pneumonia, especially in children under 5 years of age. Despite Hib vaccines protect Hib infection, seroepidemiological surveys of Hib infections have not been conducted systematically in Japan thus far. We analyzed 1,338 serum samples from 0-5-year-old children that were provided by the National Serum Reference Bank of the National Institute of Infectious Diseases (Tokyo, Japan). Serum levels of the anti-polyribosylribitol phosphate (PRP) IgG antibody against the Hib were determined using an ...
Source: Japanese Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Jpn J Infect Dis Source Type: research
Date: September 23, 2019 Issue #:  1581Summary:  Lefamulin (Xenleta– Nabriva), a semisynthetic pleuromutilin antibiotic, has been approved by the FDA for IV and oral treatment of community-acquired bacterial pneumonia (CABP) in adults. It is the first systemic pleuromutilin antibiotic to be approved in the US; retapamulin(Altabax), a 1% topical ointment for treatment of impetigo, was approved in 2007.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Amoxicillin Ampicillin/sulbactam Avelox Azithromycin Cefotaxime Cefpodoxime ceftaroline Ceftriaxone Chlamydophila pneumoniae Doxycycline Fluoroquinolones Haemophilus influenzae lefamulin Levaquin Levofloxacin Linezolid meth Source Type: research
This study retrospectively investigated vaccination-related details and postmortem findings for 57 cases of sudden death in children 2 years or younger. Data were extracted from autopsy files at the Department of Forensic Medicine, Tokai University School of Medicine. Vaccination histories were available in 50 cases based on the maternity passbook. Of the 32 cases in which any vaccines were administered, 7 infants (21.9%) had received immunization within 7 days of death. The most frequent vaccine cited as the last immunization before death was Haemophilus influenzae B. Although a temporal association of vaccines with sudde...
Source: The American Journal of Forensic Medicine and Pathology - Category: Forensic Medicine Tags: Original Articles Source Type: research
More News: Avelox | Haemophilus Influenzae (Hib) | Infectious Diseases | Japan Health | Levaquin | Moxifloxacin | Pneumonia | Respiratory Medicine